Biogen Pours Cold Water On Cross Country Spinraza Pricing Talks With Norway And Denmark
Executive Summary
Biogen is reluctant to enter joint talks with Norway and Denmark over Spinraza, but the company expects that cross-country pricing and reimbursement collaboration will become a fixture.
You may also be interested in...
Norwegian-Danish Procurement Deal Targets Biogen’s Spinraza
Norway and Denmark have signed an agreement for the joint procurement of medicines and have their eye on securing a lower price for Biogen’s orphan drug Spinraza.
BeNeLuxA Makes First Positive Reimbursement Decision On Biogen’s Spinraza
In a BeNeLuxA first, Belgium and the Netherlands have reached an agreement with Biogen to reimburse rare disease treatment Spinraza after joint health technology assessment and pricing negotiations.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.